Dar es Salaam. Tanzania has officially registered Lenacapavir, a long-acting injectable drug for the prevention and control of HIV, marking what officials describe as a significant milestone in the country’s fight against the virus.
The medicine, administered twice a year, demonstrated 100 percent efficacy in its first clinical trial conducted in Uganda in 2025.
